TransMedics
TMDX
81.07
+0.79
+0.98%
TransMedics
US · TMDX
#2536 by market cap
Listed 2019
81.07
+0.79
+0.98%
Live - 5344 symbols - heartbeat 45s ago
· 2026-10-08 07:00
Pre-market
81.15
+0.10%
After-hours
81.07
0.00%
Overnight
80.22
-1.05%
- Market cap
- 2.81B
- P/E (TTM)i
- 21.00
- P/Bi
- 5.43
- EPSi
- 4.87
- Div yieldi
- 0.00%
- 52W posi
- 22%
Reader sentiment
Are you bullish or bearish on TMDX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.99, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +37.13% YoY
Margins
- Gross margin
- 59.92%
- Operating margin
- 17.93%
- Net margin
- 31.43%
Key ratios & quality
- Enterprise valuei
- 2.84B
- Altman Z-Scorei
- 3.99
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.02M | 23.60M | 25.64M | 30.26M | 93.46M | 241.62M | 441.54M | 605.49M |
| Gross profit | 5.73M | 13.86M | 16.64M | 21.16M | 65.27M | 154.09M | 262.08M | 362.81M |
| Selling & admin expenses | 12.32M | 23.60M | 24.19M | 38.28M | 69.90M | 119.55M | 168.62M | 185.17M |
| Research & development | 13.66M | 19.87M | 18.83M | 22.30M | 26.81M | 63.27M | 55.97M | 69.06M |
| Operating profit | -20.24M | -29.60M | -26.38M | -39.43M | -31.44M | -28.73M | 37.50M | 108.58M |
| Pretax profit | -23.72M | -33.51M | -28.72M | -44.18M | -36.17M | -26.67M | 35.78M | 107.52M |
| Tax | 41.00K | 40.00K | 32.00K | 36.00K | 66.00K | -1.64M | 316.00K | -82.77M |
| Net profit | -23.76M | -33.55M | -28.75M | -44.22M | -36.23M | -25.03M | 35.46M | 190.29M |
| Basic EPS | -1 | -2 | -1 | -2 | -1 | -1 | 1 | 6 |
| Diluted EPS | -1.23 | -2.36 | -1.16 | -1.60 | -1.23 | -0.77 | 1.01 | 4.87 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 143.54M | 157.37M | 143.82M | 160.76M | 173.93M | 189.95M |
| Gross profit | 88.23M | 96.59M | 84.58M | 93.41M | 101.16M | 113.20M |
| Selling & admin expenses | 42.38M | 42.44M | 46.02M | 51.44M | 56.92M | 53.54M |
| Research & development | 17.16M | 15.93M | 15.26M | 20.70M | 24.88M | 31.63M |
| Operating profit | 27.44M | 36.57M | 23.30M | 21.27M | 13.30M | 23.74M |
| Pretax profit | 26.68M | 36.18M | 23.03M | 21.63M | 8.49M | 19.41M |
| Tax | 994.00K | 1.28M | -1.29M | -83.75M | 1.17M | 4.72M |
| Net profit | 25.68M | 34.91M | 24.32M | 105.38M | 7.32M | 14.68M |
| Basic EPS | 1 | 1 | 1 | 3 | 0 | 0 |
| Diluted EPS | 0.70 | 0.92 | 0.66 | 2.62 | 0.20 | 0.41 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 34.79M | 100.00M | 146.77M | 118.71M | 252.29M | 510.65M | 497.22M | 637.78M |
| Cash & ST investments | 20.24M | 80.69M | 125.64M | 92.45M | 201.18M | 394.81M | 336.65M | 488.37M |
| Inventory | 9.28M | 11.22M | 11.93M | 14.86M | 20.61M | 44.24M | 46.55M | 48.88M |
| Total assets | 42.16M | 105.30M | 152.03M | 134.89M | 277.15M | 706.05M | 804.08M | 1.07B |
| Total current liabilities | 12.55M | 16.12M | 11.88M | 23.24M | 23.66M | 54.93M | 59.91M | 89.31M |
| Short-term debt | -- | -- | -- | -- | 1.44M | 2.04M | 2.73M | 13.31M |
| Long-term debt | 33.67M | 34.15M | 34.66M | 35.20M | 58.70M | 506.20M | 509.31M | 502.39M |
| Total liabilities | 234,399,000.00 | 50,650,000.00 | 48,135,000.00 | 67,039,000.00 | 89,772,000.00 | 568,845,000.00 | 575,473,000.00 | 595,273,000.00 |
| Total equity | -192.24M | 54.65M | 103.89M | 67.85M | 187.38M | 137.20M | 228.60M | 473.10M |
| Retained earnings | -335.94M | -369.48M | -398.23M | -442.45M | -478.68M | -503.71M | -468.24M | -277.95M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 505.92M | 558.13M | 613.00M | 637.78M | 619.28M | 651.12M |
| Cash & ST investments | 310.14M | 400.58M | 466.17M | 488.37M | 461.74M | 472.68M |
| Inventory | 43.38M | 38.87M | 44.51M | 48.88M | 49.89M | 54.14M |
| Total assets | 837.53M | 890.52M | 946.03M | 1.07B | 1.43B | 1.46B |
| Total current liabilities | 55.60M | 56.62M | 79.72M | 89.31M | 91.92M | 98.28M |
| Short-term debt | 2.79M | 3.02M | 8.24M | 13.31M | 18.51M | 23.65M |
| Long-term debt | 510.10M | 510.89M | 506.69M | 502.39M | 498.20M | 494.00M |
| Total liabilities | 571,222,000.00 | 572,421,000.00 | 590,832,000.00 | 595,273,000.00 | 940,813,000.00 | 946,343,000.00 |
| Total equity | 266.31M | 318.10M | 355.20M | 473.10M | 494.01M | 518.05M |
| Retained earnings | -442.56M | -407.65M | -383.33M | -277.95M | -270.64M | -255.95M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -25.98M | -32.29M | -30.27M | -28.86M | -45.82M | -13.03M | 48.80M | 192.84M |
| Depreciation & amortization | 769.00K | 1.22M | 1.58M | 1.82M | 3.48M | 8.18M | 19.76M | 27.19M |
| Free cash flow | -26.40M | -32.45M | -30.72M | -32.38M | -57.72M | -192.09M | -80.94M | 133.59M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 97.37M | 74.97M | 0 | 139.85M | -- | -- | -- |
| Ending cash balance | 20.74M | 20.59M | 25.08M | 26.08M | 201.68M | 395.31M | 337.15M | 488.87M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -2.86M | 91.61M | 69.57M | 34.51M | 24.53M | 17.31M |
| Depreciation & amortization | 6.14M | 6.73M | 6.85M | 7.47M | 11.86M | 10.24M |
| Free cash flow | -29.89M | 82.53M | 61.95M | 19.00M | -12.12M | 10.22M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 310.64M | 401.08M | 466.67M | 488.87M | 480.18M | 491.11M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -134.66 | -36.27 | -51.49 | -28.39 | -15.42 | 19.39 | 54.24 |
| ROA %i | -58.64 | -45.50 | -22.34 | -30.82 | -17.59 | -5.09 | 4.70 | 20.33 |
| ROIC %i | -- | -49.64 | -22.73 | -32.25 | -18.19 | -3.28 | 7.11 | 23.06 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -22.44 | -4.34 |
| EBIT margin %i | -161.29 | -123.51 | -96.46 | -133.19 | -34.71 | -6.57 | 11.37 | 20.03 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 22.06 |
| Current ratioi | 2.77 | 6.21 | 12.36 | 5.11 | 10.66 | 9.30 | 8.30 | 7.14 |
| Quick ratioi | 1.89 | 5.41 | 11.15 | 4.23 | 9.67 | 8.34 | 7.25 | 6.41 |
| Debt / assetsi | 79.87 | 32.43 | 22.80 | 32.47 | 24.38 | 73.08 | 64.46 | 48.60 |
| LT debt / equityi | -- | 62.48 | 33.36 | 64.55 | 35.28 | 374.57 | 225.53 | 106.95 |
| Interest coveragei | -7.72 | -6.70 | -6.21 | -10.40 | -8.71 | -1.47 | 3.48 | 8.80 |
| Revenue CAGR (3Y) %i | -- | 56.07 | 49.42 | 32.47 | 58.20 | 111.23 | 144.36 | 86.42 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 22.99 | 28.21 | 32.48 | 54.24 | 45.22 | 36.28 |
| ROA %i | 6.27 | 8.69 | 10.60 | 20.33 | 15.13 | 12.88 |
| ROIC %i | 8.61 | 11.06 | 13.18 | 23.06 | 17.03 | 14.80 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 13.18 | 16.60 | 18.87 | 20.03 | 16.80 | 14.03 |
| FCF / sales %i | -- | 3.27 | 21.30 | 22.06 | 23.80 | 11.82 |
| Current ratioi | 9.10 | 9.86 | 7.69 | 7.14 | 6.74 | 6.62 |
| Quick ratioi | 8.13 | 8.93 | 6.86 | 6.41 | 6.01 | 5.87 |
| Debt / assetsi | 61.90 | 58.26 | 54.90 | 48.60 | 60.18 | 59.25 |
| LT debt / equityi | 193.62 | 162.15 | 143.89 | 106.95 | 171.03 | 162.93 |
| Interest coveragei | 4.51 | 6.25 | 7.63 | 8.80 | 6.11 | 4.42 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Liver revenue is the largest reported line at 78.07% of revenue, across 4 reported segments.
- The next-largest line, Heart revenue, is a distant second at 20.00% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Liver revenue78.07%
Heart revenue20.00%
Lung revenue1.40%
Service revenue unrelated to Organ Care System (OCS) transplant0.53%
Quote time 2026-10-08 07:00:00 · For reference only, not investment advice and not tailored to your situation.